ADIPOQ and diabetes mellitus: In vivo studies using db/db mice proved the ability of the peptide conjugate to prevent diabetes progression by reducing plasma FFAs and hypertriglyceridemia and enhancing plasma adiponectin levels as efficient as systemically administered tesa.